Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6.

@article{Biesecker1989InhibitionOA,
  title={Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6.},
  author={Greg Biesecker and Christopher M. Gomez},
  journal={Journal of immunology},
  year={1989},
  volume={142 8},
  pages={
          2654-9
        }
}
The role of the lytic complement C5b-9 membrane attack complex (MAC) in acute passive transfer experimental autoimmune myasthenia gravis (EAMG) produced in rats was investigated by in vivo inhibition of MAC formation with anti-C6 Fab. Anti-C6 Fab totally inhibited in vitro serum hemolytic activity, but did not consume or inhibit early complement pathways. Injection of rats with 0.12 mg/ml anti-C6 Fab reduced serum C6 to 8% and inhibited the muscle weakness, electrophysiologic abnormalities and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 40 CITATIONS

Targeting complement system to treat myasthenia gravis.

  • Reviews in the neurosciences
  • 2014
VIEW 4 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Animal models of myasthenia gravis: utility and limitations.

  • International journal of general medicine
  • 2016
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

The immunopathogenesis of myasthenia gravis.

  • Handbook of clinical neurology
  • 2008
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Effect of myasthenic immunoglobulin G on motor end-plate morphology

  • Journal of Neurology
  • 2003
VIEW 9 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Complement Therapeutics in Autoimmune Disease

  • Front. Immunol.
  • 2019
VIEW 1 EXCERPT
CITES BACKGROUND